ArriVent Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data
ArriVent BioPharma reported initial Phase 1 data showing a 44.8% objective response rate among pretreated colorectal cancer patients at the 6 mg/kg dose.
ArriVent BioPharma reported initial Phase 1 data showing a 44.8% objective response rate for ARR-217 in pretreated colorectal cancer patients at the 6 mg/kg dose.Key Highlights:Original SEC Filing: ArriVent BioPharma, Inc. [ AVBP ] - 8-K - Oct. 26, 2026This is an AI-powered summary. It may contain…